MYRIAD GENETICS INC MYGN
Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs.
Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care. We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission. We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $638.6M | $851.1M | $743.7M | $728.7M | $740.5M |
| Cost of revenue | $247.9M | $252.2M | $236.2M | $202.0M | — | — | — | — | $145.2M | $132.8M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — | — | — | — | $583.5M | $607.7M |
| R&D | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M | $77.2M | $85.9M | $70.8M | $74.4M | $70.6M |
| SG&A | $256.8M | $275.9M | $283.7M | $247.9M | $537.8M | $507.3M | $556.6M | $435.0M | $439.9M | $359.2M |
| Total operating expenses | $963.8M | $708.9M | $774.4M | $617.0M | $881.1M | $870.3M | $843.5M | $621.8M | $684.7M | $587.1M |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M | -$231.7M | $7.6M | $121.9M | $44.0M | $153.4M |
| Interest expense | $10.5M | $2.8M | $2.9M | $3.2M | $6.6M | $10.8M | $12.0M | $3.2M | $6.0M | $300.0K |
| Pre-tax income | -$395.1M | -$123.5M | -$262.2M | -$140.6M | -$57.1M | -$223.3M | $0 | $120.1M | $36.2M | $156.0M |
| Income tax | $29.2M | $3.8M | $1.1M | $28.6M | $29.9M | $23.7M | $4.4M | $13.0M | $19.0M | $38.8M |
| Net income | -$366.0M | -$127.0M | -$263.0M | -$112.0M | -$27.0M | -$199.5M | $4.6M | $133.3M | $17.4M | $117.2M |
| EPS, basic | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 | -2.69 | 0.06 | 1.92 | 0.25 | 1.67 |
| EPS, diluted | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 | -2.69 | 0.06 | 1.85 | 0.25 | 1.60 |
| Shares, diluted (wtd. avg.) | 92.6M | 90.6M | 82.8M | 80.6M | 78.0M | 74.3M | 76.0M | 72.0M | 68.8M | 73.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $149.6M | $102.4M | $132.1M | $66.4M | $258.8M | $117.0M | $93.2M | $110.9M | $102.4M | $68.5M |
| Short-term investments | — | $0 | $8.8M | $58.0M | $81.4M | $33.7M | $43.7M | $69.7M | $48.3M | $90.5M |
| Receivables | $115.3M | $121.2M | $114.3M | $101.6M | $91.3M | $89.5M | $133.9M | $99.5M | $89.2M | $91.7M |
| Inventory | $30.6M | $27.5M | $22.0M | $20.1M | $15.3M | $27.1M | $31.4M | $34.3M | $42.2M | $38.3M |
| Total current assets | $332.6M | $298.0M | $313.6M | $274.6M | $484.8M | $389.4M | $348.6M | $327.6M | $301.7M | $314.5M |
| Property, plant and equipment | $114.0M | $117.4M | $119.0M | $83.4M | $43.5M | $40.7M | $57.3M | $43.2M | $51.1M | $58.3M |
| Goodwill | $51.6M | $286.3M | $287.4M | $286.8M | $239.2M | $329.2M | $417.2M | $318.6M | $316.1M | $195.3M |
| Other intangibles | $153.4M | $262.4M | $349.5M | $379.7M | $404.1M | $576.5M | $684.7M | $455.2M | $491.5M | $227.5M |
| Total assets | $706.6M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880.5M |
| Accounts payable | $30.0M | $32.3M | $25.8M | $28.8M | $29.6M | $20.5M | $33.3M | $26.0M | $22.0M | $21.1M |
| Total current liabilities | $133.8M | $164.1M | $155.9M | $137.2M | $204.3M | $145.9M | $117.8M | $102.2M | $217.5M | $72.3M |
| Long-term debt | $119.9M | $39.6M | $38.5M | $0 | $0 | $224.8M | $233.5M | $9.3M | $99.1M | — |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M | $537.8M | $473.8M | $209.2M | $440.9M | $132.4M |
| Retained earnings | -$1.12B | -$756.8M | -$629.5M | -$366.2M | -$254.2M | -$227.0M | $25.6M | $54.1M | -$79.2M | -$73.2M |
| Total equity | $368.0M | $701.1M | $783.2M | $885.8M | $967.8M | $881.0M | $1.09B | $966.1M | $767.4M | $741.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.8M | -$8.7M | -$110.9M | -$106.3M | $18.6M | $60.7M | $83.7M | $115.9M | $106.2M | $166.3M |
| Depreciation and amortisation | $19.5M | $19.5M | $19.1M | $11.6M | $12.1M | $11.0M | $13.7M | $17.1M | $15.0M | $14.1M |
| Stock-based compensation | $35.2M | $49.8M | $40.7M | $38.1M | $36.3M | $25.2M | $33.5M | $27.1M | $29.9M | $31.6M |
| Capital expenditure | — | — | — | $45.3M | $18.0M | $10.2M | $8.6M | $8.4M | $6.1M | $5.0M |
| Investing cash flow | -$27.4M | -$11.9M | $31.9M | -$77.5M | $274.4M | $19.3M | -$286.4M | -$11.6M | -$146.3M | -$91.4M |
| Financing cash flow | $64.2M | -$7.4M | $152.9M | -$8.0M | -$150.6M | -$10.0M | $182.3M | -$95.0M | $71.8M | -$68.3M |
| Buybacks | — | — | — | — | $0 | $0 | $50.0M | $0 | $31.6M | $162.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000899923-26-000031.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $740.5M | $728.7M | $743.7M | $851.1M | $638.6M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Gross profit | $607.7M | $583.5M | — | — | — | — | $476.4M | $517.0M | $585.4M | $576.6M |
| Net income | $117.2M | $17.4M | $133.3M | $4.6M | -$199.5M | -$27.0M | -$112.0M | -$263.0M | -$127.0M | -$366.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| TKNO | Alpha Teknova, Inc. | $344.7M | — | 7.4% |